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Abstract
Background: Previously we performed a linkage scan of 638 African American affected sibling pairs (ASP) with
type 2 diabetes (T2D) enriched for end-stage renal disease (ESRD). Ordered subset linkage analysis (OSA) revealed a
linkage peak on chromosome 7p in the subset of families with earlier age of T2D diagnosis.
Methods: We fine mapped this region by genotyping 11 additional polymorphic markers in the same ASP and
investigated a total of 68 single nucleotide polymorphisms (SNPs) in functional candidate genes (GCK1, IL6, IGFBP1
and IGFBP3) for association with age of T2D diagnosis, age of ESRD diagnosis, duration of T2D to onset of ESRD,
body mass index (BMI) in African American cases and T2D-ESRD in an African American case-control cohort. OSA of
fine mapping markers supported linkage at 28 cM on 7p (near D7S3051) in early-onset T2D families (max. LOD =
3.61, P = 0.002). SNPs in candidate genes and 70 ancestry-informative markers (AIMs) were evaluated in 577 African
American T2D-ESRD cases and 596 African American controls.
Results: The most significant association was observed between ESRD age of diagnosis and SNP rs730497, located
in intron 1 of the GCK1 gene (recessive T2D age-adjusted P = 0.0006). Nominal associations were observed with
GCK1 SNPs and T2D age of diagnosis (BMI-adjusted P = 0.014 to 0.032). Also, one IGFBP1 and four IGFBP3 SNPs
showed nominal genotypic association with T2D-ESRD (P = 0.002-0.049). After correcting for multiple tests, only
rs730497 remanined significant.
Conclusion: Variant rs730947 in the GCK1 gene appears to play a role in early ESRD onset in African Americans.
Background
A genome wide linkage scan was performed on 638 Afri-
can American affected sibling pairs (ASPs) with type 2
diabetes (T2D) from 247 families; 166 families contained
at least one ASP concordant for diabetic end-stage renal
disease (T2D-ESRD) [1]. Ordered subset analysis (OSA)
revealed a linkage peak on chromosome 7p in the subset
of T2D families with an early age of diagnosis (29% of
pedigrees, max. LOD = 3.85, P = 0.003 for the change in
L O Ds c o r e )[ 1 ] .T 2 D - E S R Ds u b s e t sw i t hl o w e rb o d y
mass index (BMI) (64% of pedigrees, max. LOD = 3.93, P
= 0.010) and longer duration from T2D diagnosis to
ESRD onset (37% of pedigrees, max. LOD = 3.59, P =
0.010) also showed evidence for linkage at this locus [2].
Fine mapping of this region using the same African
American families was undert a k e ni no r d e rt ol o c a l i z e
the peak and to determine the primary phenotype of
association. There are several plausible diabetes and
nephropathy candidate genes in the resulting region of
interest, including glucokinase isoform 1 (GCK1), inter-
leukin-6 (IL6), insulin growth factor binding protein 1
(IGFBP1) and insulin growth factor binding protein 3
(IGFBP3).
Mutations of GCK have been identified in subjects
with maturity-onset diabetes of the Young (MODY)
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in this gene have also been shown to be associated with
typical T2D [5-7]. A dinucleotide (CA)n repeat element
located approximately 10 kb 3’ to the coding region has
also shown association with T2D across several diverse
ethnic populations [8-10].
The cytokine interleukin 6 (IL-6) is an essential regu-
lator of the acute phase response associated with T2D
and diabetic nephropathy [11,12]. Variants in the IL6
promoter region have been shown to affect promoter
strength [13].
The insulin like growth factors 1 and 2 circulate tightly
bound to IGFBP-1 and IGFBP-3. A cross-sectional study
of T2D cases and controls found that polymorphisms in
IGFBP3 was associated with levels of HbA1c [14]. Also, in
vivo and in vitro studies have demonstrated that IGFBP-3
is a potent insulin antagonist [15].
We fine mapped the region of interest using addi-
tional microsatellite markers, and investigated associa-
tions with SNPs in four plausible candidate genes with
age of T2D diagnosis, age of ESRD diagnosis, duration
o fT 2 Dt oo n s e to fE S R D ,B M Ia n dT 2 D - E S R Di na n
African American cohort.
Methods
Selection criteria and recruitment of African American
families
This study was conducted under Institutional Review
Board approval from Wake Forest University School of
Medicine and adhered to the tenets of the Declaration
of Helsinki. All participants provided written informed
consent. Clinical characteristics and recruitment of Afri-
can American patients have been described previously
[1,2]. DNA samples were collected from self-described
African American families with multiple T2D affected
members. Briefly, families were originally identified
through a proband with impaired renal function asso-
ciated with T2D. Medical records were reviewed to ver-
ify the etiology of the nephropathy. Impaired renal
function was attributed to diabetes in the presence of
the following criteria: serum creatinine ≥ 1.5 mg/dl, dia-
betes for >10 years or presence of proliferative diabetic
retinopathy, and/or proteinuria ≥ 500 mg/24 h or >100
mg/dl, in the absence of other known causes of renal
failure. T2D was diagnosed in patients developing dia-
betes after the age of 35 years and treated at the time of
recruitment with oral hypoglycemic agents, insulin, or
diet and exercise, where treatment was considered per-
manent (i.e., excluding steroid-induced diabetes and
gestational diabetes). The family set for the genome-
wide scan comprised 247 African American families
with 638 ASPs, totaling 675 individuals.
Case-control subjects
Identification, clinical characteristics, and recruitment
of African Americans and European American patients
and controls have been described previously [16].
Briefly, 577 unrelated African American patients with
T2D, born in North Carolina, South Carolina, Georgia,
Tennessee or Virginia, were recruited from dialysis
facilities. T2D was diagnosed if patients reported an
initial diagnosis of diabetes after 35 years of age,
received dietary therapy or hypoglycemic agents in the
absence of insulin alone for at least 1 year after diagno-
sis, and were currently receiving diabetes medications.
Case subjects had severe diabetes accompanied by
nephropathy, and T2D at least 5 years prior to initiat-
ing renal replacement therapy, background or greater
diabetic retinopathy and/or > 3+ proteinuria on urina-
lysis in the absence of other causes of nephropathy.
Nondiabetic control subjects were recruited from the
same geographic region: 596 were African American
and 39 European American without a prior diagnosis
of T2D or renal disease, born in the same southeastern
states, were recruited. DNA extraction was performed
using the PureGene system (Gentra Systems, Minnea-
p o l i s ,M N ) .D N Aw a sa l s oo b t a i n e df r o m4 4Y o r u b a
Nigerians (YRI) from the National Institute of General
Medical Sciences Human Variation Collection (Coriell
Cell Repositories, Camden, NJ).
For admixture analyses, 39 unrelated European Ameri-
can controls were recruited using the same criteria as
African American controls. DNA was also obtained
from 44 YRI from the National Institute of General
Medical Sciences Human Variation Collection (Coriell
Cell Repositories, Camden, NJ).
Genotyping for fine mapping
Eleven fine mapping microsatellites at an average spa-
cing of 4 cM were selected from the Marshfield Center
of Medical Genetics database http://research.marshfield-
clinic.org/genetics/ and the Genome Database http://
www.gdb.org/gdb/. The polymerase chain reaction
(PCR) was used to incorporate fluorescently labeled pri-
mers from Integrated DNA Technologies, Inc. (Coral-
ville, IA) and Applied Biosystems (Foster City, CA) into
PCR products, which were then electrophoresed on an
ABI PRISM 3700 DNA Analyzer and results analyzed
with Genescan Analysis Software (Applied Biosystems,
Foster City, CA). Electropherograms were imported into
GeneMapper (Applied Biosystems, Foster City, CA) for
binning and allele calling. Familial relationships and
Mendelian inconsistencies were checked using Prest [17]
and PedCheck [18]. Inconsistent familial relationships
were discarded from further analysis.
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A series of OSA [19] were computed to investigate the
influence of a pedigree’s mean age of diagnosis, BMI
and duration of T2D to ESRD onset. The statistical sig-
nificance of the change in the LOD score was evaluated
by a permutation test under the null hypothesis that the
ranking of the covariate is independent of the LOD
score of the family on the target chromosome. Thus, the
families were randomly permuted with respect to the
covariate ranking, and an analysis proceeded as above
for each permutation of these data. The resulting
empirical distribution of the change in the LOD scores
yielded a chromosome-wide P value (ΔP).
Diabetes candidate gene selection and genotyping
Plausible functional candidate genes (IL6, GCK1,
IGFBP1 and IGFBP3) that lie under the intersection of
the optimal linkage peaks for early age of T2D, lower
BMI and longer duration to ESRD was selected (Figure
1). This regions roughly spans the distance between
D7S513 and D7S1818. In the absence of a comprehen-
sive African American SNP database of allele frequen-
cies, we used the genotypic data of the YRI and CEPH
Europeans (CEU) from the International HapMap pro-
ject (HapMap #20, NCBI B35 assembly). Using the lar-
gest gene transcript plus 5 kb upstream and
downstream of the gene, we selected YRI HapMap SNPs
with a minor allele frequency (MAF) ≤ 0.05, excluded
SNPs with an Illumina designability score < 1.0, then
used the aggressive tagging option of Tagger [20] imple-
mented in Haploview 3.2 [21]. Next, we selected CEU
HapMap SNPs with MAF ≤ 0.05, forced the exclusion
of Illumina-undesignable SNPs and inclusion of the
already selected YRI tagSNPs, then used the aggressive
tagging option of Tagger [20] to select any additional
tags required to capture CEU variation. In addition, we
added previously associated SNPs from the literature,
yielding a total of 68 SNPs: glucokinase isoform 1
(GCK1,2 4S N P s ) ;i n t e r l e u k i n - 6( IL6, 17 SNPs); insulin
growth factor binding protein 1 (IGFBP1, 16 SNPs) and
insulin growth factor binding protein 3 (IGFBP3,1 1
SNPs).
Genotyping was performed by Illumina Genotyping
Services (Illumina Inc., San Diego, CA). Six SNPs were
genotyped using iPlex methodology on a MassARRAY
system (Sequenom Inc., San Diego, CA) [22]: IL6
rs1800797; GCK1 rs741038, rs2971672 and IGFBP1:
rs1496495, rs1908751, rs9658239. Primer sequences are
available on request. The genotyping success rates were
>96.5 in cases and >96.1% in controls. For quality con-
trol purposes each plate contained 2 duplicate samples
and 4 inter-plate controls. Concordance between dupli-
cate samples included in the genotyping was >98.9%.
Genotyping for admixture analyses
Seventy biallelic Admixture Informative Markers
(AIMs), selected to maximize European and African
allele frequency differences and sample all non-acro-
centric arms of the autosomal genome, were genotyped
by Illumina Inc.’s Custom Genotyping Service (Illumina
Inc., San Diego, CA) in 577 African American cases, 596
African American controls, 44 YRI and 39 European
Americans. Primer sequences are available on request.
Genotyping success rates for AIMS were >97.4% in Afri-
can American cases and >95.6% in African American
controls.
Statistical Analysis
Characteristics were compared and tested for significant
differences using c
2 tests for categorical variables, and
one-way ANOVA test for continuous variables. Hardy-
Weinberg equilibrium (HWE) was assessed using the c
2
goodness-of-fit statistic at a significance level of ≤ 0.01.
Haplotype block structure was established using Haplo-
view 3.2 [21], using the block definition from Gabriel et
al. [23].
Tests of association under the three ap r i o r igenetic
tests of association (dominant, additive and recessive)
are reported. Due to a lack of validity of the large sam-
ple c
2 test statistic, only the dominant model was con-
sidered for SNPs with ten or fewer individuals that were
homozygous for the minor allele.
Quantitative trait (duration of T2D to ESRD onset,
BMI, age at T2D and ESRD onset) association analysis
for all SNPs was performed using a series of analysis of
variance (ANOVA) tests implemented in QSNPGWA
[24].
SNPs that showed nominal evidence for association
with age of T2D onset were adjusted by BMI. Addition-
a l l y ,E S R Da g e ,d u r a t i o no fT 2 Dt oE S R Do n s e ta n d
BMI were adjusted for age of T2D onset. All analyses
were adjusted using linear regression on a priori genoty-
pic models, and conducted using Stata 10 (College Sta-
tion, TX).
Unadjusted odds ratios (ORs) and 95% confidence
intervals (CI) in the case-control population were com-
puted using SNPGWA to test all SNPs for genotypic
association with T2D-ESRD [25]. SNPs that showed
nominal evidence for association were then tested using
a permutation test (1,000 permutations) as implemented
in SNPGWA.
Individual ancestral proportions were calculated using
an expectation-maximization (EM) algorithm (FRAPPE)
[26] under a two-population model. Logistic regression
tests of genetic models included adjustments for indivi-
dual estimates of African ancestry, implemented in the
program SNPADMIX [25].
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sided test at an alpha level of ≤ 0.05, to detect an OR of
1.30 was utilized to approximate study power [27].
We report nominally significant associations at the P ≤
0.05 level. To correct for multiple tests at the gene level
the conservative Bonferonni method was used, with a P-
value ≤ 0.0007 considered significant evidence for asso-
ciation when assuming independence based on LD.
Results
Fine mapping linkage analyses
OSA including the new fine mapping microsatellite data
continued to support linkage at 28 cM on chromosome
7p, closest to D7S3051, in early-onset T2D families.
Twenty-one percent of the pedigrees account for a maxi-
mum LOD = 3.61 (P = 0.002) with a mean age at diagno-
sis 29.5 ± 3.0 years vs. mean age at diagnosis of the
unlinked families 44.5 ± 7.3. Although the max. LOD
score dropped (from 3.85, P = 0.003 in the genome scan)
the LOD-1 interval increased from 11.5-38.2 cM to 11.5-
49.5 cM. There was no significant difference (P =0 . 5 6 )
between mean BMI in the linked early-onset families
(31.5 kg/m
2 ± 7.62) versus the unlinked (31.8 kg/m
2 ±
7.51) pedigrees. The evidence for linkage in subsets of
T2D-ESRD families with lower BMI (64% of pedigrees;
max. LOD = 2.20, P = 0.11) and longer duration of dia-
betes before onset of ESRD (56% of pedigrees; max. LOD
= 2.81, P = 0.20) was no longer significant (Figure 1).
Case-control population
Characteristics of the study population used for tests of
association with positional candidate genes are shown in
Table 1. The mean age of examination for the non-dia-
betic controls is 7.5 years later than the mean age of
onset for diabetes in the T2D-ESRD participants. The
estimated mean proportion of African ancestry in the
case subjects was 81.7 ± 13.3 in T2D-ESRD cases and
79.1 ± 13.1 in controls (P = 0.0008).
Hardy-Weinberg Equilibrium and linkage disequilibrium
All SNPs in candidate genes were examined for departures
from HWE assumptions in cases and controls separately.
Deviations from HWE (P ≤ 0.01) were observed for IL6
rs1474347 in controls (P = 0.002) and IGFBP1 rs1496495
in cases (P = 0.001). Although inconsistent with HWE
proportions, these SNPs were retained for exploratory ana-
lyses, however there was no evidence for association of
these SNPs with any of the traits investigated.
The 24 GCK1 SNPs fell into five blocks of LD, with
pairwise values of D’ values ranging from 0.41-1.00, and
r
2 = 0.003-0.76. D’ values between the 17 IL6 SNPs ran-
ged from 0.34-1.00, with r
2 values of 0.0002-0.82, result-
ing in one high LD block. The 16 IGFBP1 SNPs fell
within three blocks of high LD, with SNPs in the 3’UTR
contained in block 2 (D’ = 0.88-0.99; r
2 = 0.02-0.34) and
the 11 genotyped IGFBP3 SNPs fell within two blocks of
LD (data not shown).
Analyses with age at diagnosis of T2D and age at ESRD
Association analyses revealed two GCK1 SNPs nominally
associated with T2D age at diagnosis and five GCK1 SNPs
associated with age at ESRD onset (Table 2). The most sig-
nificant result from the entire dataset was the association
with intron 1 SNP rs730497 and age at ESRD onset (P =
0.0004; T2D age-adjusted P = 0.0006). The homozygote
recessive genotype (”AA“) for IL6 SNP rs2069849, located
in exon 5, was nominally associated with age at ESRD
onset (T2D age-adjusted P = 0.013). SNPs in IGFBP1 and
IGFBP3 were not associated with T2D age at diagnosis or
ESRD onset (Additional file 1, Table S1 and S2).
Analyses with duration of T2D to ESRD onset
Association results for duration of T2D to ESRD onset
are presented in Additional file 1, Table S3. IL6 SNP
rs1554606 was nominally associated (T2D age-adjusted
P = 0.006) with shorter duration of T2D to ESRD onset
(Table 2; 15.8 ± 13.0 years for “AA“ genotype, compared
with 20.0 ± 14.1 years for “CC“/”CA“). Results are
further summarized in Table 2.
Analyses with BMI
Association results for BMI are shown in Table 2.
IGFBP1 and IGFBP3 SNPs were not associated when
adjusted for age of T2D diagnosis (P value = 0.067 and
0.120 respectively). Single SNP association results for
Figure 1 Chromosome 7p Ordered Subset Analysis.
Chromosome 7p fine mapping linkage results showing the Ordered
Subset Analyses of early age at type 2 diabetes diagnosis (red),
lower body mass index (green) and longer duration of type 2
diabetes mellitus to development of end stage renal disease (blue).
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S4.
Analyses with T2D-ESRD in the African American case-
control population
Single SNP genotypic association results (P ≤ 0.05) for
T2D-ESRD are shown in Additional file 1, Table S5.
Nominal evidence of association was observed with
IGFBP3:t w op r o m o t e rS N P s :r s 9 0 3 8 8 9( d o m i n a n tP =
0.014; admixture-adjusted Pa = 0.029), rs924140 (addi-
tive P = 0.019; Pa = 0.033) and two SNPs located in
intron 3; rs10255707 (dominant P =0 . 0 0 5 ;Pa = 0.01)
and rs3110697 (recessive P = 0.002; Pa =0 . 0 0 3 ) .N o m -
inal evidence of association was also detected with
IGFBP1 rs9658233 located in the 3’ UTR region. GCK1
and IL6 SNPs showed no evidence of association with
T2D-ESRD (Additional file 1, Table S6). Genotype fre-
quencies and counts for each SNP are shown in Addi-
tional file 1, Table S7.
Tagger [20] results indicated that 2- or 3-SNP haplo-
types were not required to capture ungenotyped YRI
and CEU HapMap SNPs in these genes.
Discussion
Evidence of linkage on chromosome 7p in families with
age of T2D diagnosis, ESRD onset, lower BMI and
longer duration to ESRD was detected in an earlier
study of African American families [1,2]. These results
generated our interest in genotyping additional poly-
morphic markers to refine the linkage peak and explore
positional candidate genes. Fine mapping analyses con-
tinued to support evidence for linkage at 7p in a subset
of T2D families with an early age of diagnosis. Although
this linkage peak does not appear to have been reported
in other populations, two recent reports detected mod-
est evidence of linkage to T2D in the same region in
African American families from the GENNID Cohort
[28] and an African American population from South
Carolina [29].
T h ep r e s e n ts t u d yd e m o n s t r a t e st h a tGCK1 rs730497
recessive “AA” genotype is strongly associated with early
age ESRD onset (Table 2). GCK1, a strong functional
candidate for T2D, appears to play a role in susceptibil-
ity to early age of ESRD in African Americans. We
observed an approximately 6 year shorter duration of
T2D to ESRD and early age of T2D onset with recessive
“AA” homozygotes compared with “GG” homozygotes
and heterozygotes (Additional file 1, Tables S1 and S3).
Earlier reports suggest that nephropathy is rarely obe-
served in persons with GCK1 mutations [30]. MODY is
characterized as non-ketoticT2D that is inherited by an
autosomal dominant manner [31-33], with early onset
(usually before the age of 25). MODY is often asympto-
matic mild hyperglycemia, which can go undetected for
prolonged periods of time which can lead to diabetic
complication later in adulthood. Hence, it is plausible
that in the presence of hyperglycemia and increased
BMI (mean BMI 30.8 kg/m
2 ± 7.1; Additional file 1,
Table S4) along with the rs730497 recessive genotype
results in ESRD progression. In addition, several reports
have shown that MODY genes segregate in late onset
T2D cases and families [34-36]. In an effort to reduce
the likelihood of including potential MODY2 patients,
only individuals with T2D onset over the age of 35 were
ascertained as probands.
Recently, Paré et al.[ 3 7 ]r e p o r t e dt h a tv a r i a n t
rs730497 is associated with an increase of 0.03% HbA1c
levels (P = 2.8 × 10
-12) in non-diabetic European Ameri-
cans from the Women’s Genome Health Study (WGHS)
and participants from the Boston metropolitan area.
T h eM A Fo ft h er s 7 3 0 4 9 7A“risk"allele was similar in
African American cases (0.20) and previously reported
European Americans from WGHS (0.17) [37]. Several
studies have shown a strong correlation between
increased levels of HbA1c and nephropathy [38]. The
relationship between rs730497 minor “A“ allele and
ESRD progression is unknown, however, marker
rs730497 is located 4.8 kb from exon 1 and 30.7 kb
f r o me x o n2 .T h es l i g h t l ym o r ec o m m o nG allele
Table 1 Characteristics of African American subjects
Trait T2D-ESRD Cases Controls
n* n*
% Female (n) 577 61% (352) 596 51% (306)
Age at exam (years ± SD) 541 62.2 ± 10.3‡ 448 49.3 ± 9.8
Age at T2D diagnosis (years ± SD) 544 41.8 ± 11.6 - -
Age at ESRD diagnosis (years ± SD) 560 59.0 ± 10.5 - -
BMI (kg/m
2) 559 29.6 ± 7.0† 450 29.8 ± 7.1
T2D duration to ESRD onset (years ± SD) 511 20.3 ± 10.5 - -
Mean African Ancestry 577 81.7 ± 13.3‡ 596 79.1 ± 13.1
*n = number with data available. ‡ Mean differs significantly between cases and controls P-value < 0.001. †Reflects dry weight on dialysis. All cases were
diagnosed with T2D and ESRD.
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panzee sequence.
Nominal associations with MODY gene GCK1 was
also observed with T2D age at diagnosis (Table 2). Four
GCK1 S N P sw e r ef o u n dt ob ea s s o c i a t e dw i t hT 2 Dr i s k
(recessive model: OR ranging from 1.36-1.87) in a case-
control population from Finland [39]. Bonnycastle et al.
[39] observed an 87% increased T2D risk with marker
rs882020. Marker rs2908296 is approximately 14.7 kb
from rs882020; it is plausible that these variants may tag
or be in LD with the causal variant(s). The reported
associated SNPs (rs2284769, rs12534623, rs2268573 and
rs882020) [39] and the dinucleotide repeat (D7S531) in
Mauritian Creoles [8], African Americans [9], and South
Indians [10], were not directly investigated in our Afri-
can American population due to our HapMap-coverage
based SNP selection process, however the 24 GCK1
SNPs genotyped captured all 32 HapMap GCK1 SNPs
with MAF > 5% with r
2 values > 0.80.
IL6 SNP rs2069849, located in exon 5, was nominally
associated with earlier age of ESRD onset. This variant
causes a synonymous coding change for phenylalanine
at position 201 (F201), which may alter mRNA stability
and translation. Promoter polymorphisms rs1800795
and rs1800796 have shown association with T2D and
diabetic nephropathy respectively [40-42]. We investi-
gated these two SNPs in our African American popula-
tion (Additional file 1, Table S6) and, consistent with a
study conducted in a larger population of T2D cases
and non-T2D controls [43], did not observe association
with T2D-ESRD. The MAF for promoter SNPs
rs1800797, rs1800796 and rs1800795 in African Ameri-
can (controls: 0.07 0.09; 0.07, respectively; cases 0.05;
0.11; 0.06, respectively) are comparable with the YRI fre-
quencies (MAF = 0.0; 0.09; 0.0), but contrast with those
of the European American controls (MAF = 0.48; 0.04;
0.53). The lack of association may be due to the reduced
prevalence of the risk alleles in our African American
population.
Modest associations with T2D-ESRD were also
detected with one IGFBP1 (rs9658233) and four IGFBP3
SNPs (rs10255707, rs3110697, rs924140 and rs903889).
The major “T” allele for SNP rs9658233, located in the
downstream region of IGFBP1,a p p e a r st oc o n f e rr i s k
with T2D-ESRD, with OR between 1.25-1.35 (Additional
file 1, Table S5). In contrast, having at least one copy of
the minor allele for IGFBP3 variants rs3110697 and
rs924140 appear to protect against T2D-ESRD, with OR
between 0.60-0.82 (Additional file 1, Table S5). The fre-
quencies of rs3110697 and rs924140 located in intron 3
Table 2 Nominally significant (P < 0.05) single-SNP genotypic tests of association with T2D age at diagnosis, ESRD age
at onset, BMI on dialysis, and duration of T2D to ESRD onset.
Phenotype Gene Marker Major/Minor
alleles
MAF
Case
1/1
Mean ±
SD (n)
1/2
Mean ±
SD (n)
2/2
Mean ±
SD (n)
Dominant P-
value
Additive P-
value
Recessive P-
value
ESRD age IL6 Rs2069849 G/A 0.15 59.0 ± 10.5
(419)
59.8 ± 10.4
(140)
53.7 ± 10.4
(16)
0.896 0.581 0.040 (0.013)
a
Duration of T2D
to ESRD
IL6 rs1554606 C/A 0.34 20.2 ± 13.7
(255)
19.7 ± 14.7
(245)
15.8 ± 13.0
(68)
0.247 0.052 0.007 (0.006)
a
T2D age GCK1 rs2908296 C/A 0.35 41.6 ± 11.0
(235)
42.8 ± 12.2
(277)
38.0 ± 10.3
(63)
0.733 0.313 0.007 (0.014)
b
T2D age GCK1 rs12673242 A/G 0.37 41.3 ± 11.4
(236)
43.2 ± 11.9
(258)
39.0 ± 11.2
(81)
0.38 0.606 0.023 (0.032)
b
ESRD age GCK1 rs2908296 C/A 0.35 59.2 ± 10.0
(235)
59.4 ± 11.2
(277)
56.1 ± 8.7
(63)
0.632 0.157 0.027 (0.133)
a
ESRD age GCK1 rs2971676 G/A 0.24 59.4 ± 10.4
(328)
59.0 ± 10.8
(217)
54.4 ± 8.8
(30)
0.328 0.092 0.02 (0.035)
a
ESRD age GCK1 rs2971675 C/A 0.23 59.5 ± 10.5
(338)
58.7 ± 10.8
(210)
54.5 ± 8.4
(27)
0.2 0.065 0.033 (0.029)
a
ESRD age GCK1 rs730497 G/A 0.2 58.9 ± 10.4
(367)
60.0 ± 10.6
(180)
51.5 ± 8.6
(25)
0.989 0.206 0.0004
(0.0006)
a
ESRD age GCK1 rs2908289 G/A 0.27 58.5 ± 10.5
(315)
60.6 ± 10.7
(211)
55.1 ± 8.8
(49)
0.223 0.827 0.008 (0.129)
a
BMI IGFBP1 rs1908751 C/T 0.33 29.8 ± 7.3
(254)
29.2 ± 6.7
(243)
31.6 ± 7.1
(60)
0.838 0.436 0.043 (0.067)
a
BMI IGFBP3 rs10255707 G/A 0.04 29.9 ± 7.1
(511)
27.3 ± 5.4
(33)
23.5 ± 7.4
(2)
0.022 (0.120)
a --
Duration of T2D
to ESRD
IGFBP3 rs3110697 G/A 0.35 21.3 ± 15.7
(234)
18.5 ± 12.7
(270)
19.8 ± 14.2
(63)
0.027 (0.067)
a 0.055 0.586
Test models refer to the minor allele. *Only the dominant model was considered where the minor allele homozygote count was <10. Bold: P-values < 0.05.
Unadjusted P values without parentheses and P values with parentheses adjusted for
aT2D age- and
bBMI.
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Page 6 of 9and the promoter region of IGFBP3 and rs9658233 of
IGFBP1 more closely resemble the frequencies of the
HapMap YRI samples, suggesting African influence for
these markers. Several genome wide association studies
performed in European populations have replicated
associations with SNPs in IGF2BP2 [44-47], implicating
a role for the IGF pathway and T2D susceptibility.
We also note in the results that 2- and 3-SNP moving
windows analyses were not required to capture ungeno-
t y p e dY R Ia n dC E UH a p M a pS N P si nIL6, GCK1,
IGFBP1 and IGFBP3.
One limitation of this study is that all controls did not
have measures of diabetes status or renal impairment.
Serum glucose values were obtained for 42.9% (256 indi-
viduals) of the African American controls (mean 93.6
mg/dl). Five of these individuals had glucose levels
greater than 126 mg/dl. Four of these measures were
non-fasting and the fifth had unknown dietary status,
suggesting the overall misclassification rate of controls
is likely to be below 2%. While this has not impacted
our ability to detect an association, this may have
reduced our power to detect more subtle influences of
additional variants, and underestimate effect sizes.
While adjustments for admixture reduced the strength
for the observed associations with T2D-ESRD (Addi-
tional file 1, Table S5), associations with IGFBP1
rs9658233 and IGFBP3 (rs10255707, rs3110697,
rs924140 and rs903889) remained nominally significant.
Multiple comparisons were corrected by conservative
Bonferroni method (P ≤ 0.00005) however, when assum-
ing independence based on LD, one would consider a P-
value ≤ 0.0007 as evidence for association, only SNP
rs730497 remained significant (T2D age-adjusted P =
0.0006).
We estimate 65.7% power to detect an OR of 1.30 at a
significance level of 0.05 in the case-control cohort [27].
We have confirmed linkage to early-onset T2D on
chromosome 7p, and examined common variants
across positional candidate genes GCK1, IL6, IGFBPI
and IGFBP3.Av a r i a n to ft h eGCK1 gene, rs730497,
appears to play a role in susceptibility to earlier age of
ESRD onset in African Americans. This may not repre-
sent the “true” casual variant but may be in LD with a
functional SNP. Denser SNP genotyping and direct
sequencing along with functional studies investigating
intron 1 of the GCK1 gene are imperative to investigate
the etiology of ESRD risk. It is plausible that multiple
rare variants in this region of the gene may contribute
to this phenotype. In addition, other candidates under
the LOD-1 interval, includes the growth factor recep-
tor-bound protein 10 (GRB10)[ 4 8 , 4 9 ]a n dI G F 2
mRNA binding protein 3 (IGF2BP3), warrant
investigation.
Conclusion
Our findings support that intron 1 of the GCK1 play a
role with ESRD risk. Further studies in other popula-
tions and functional studies may be warranted.
Additional file 1: Supplementary tables. Supplemental tables S1-S6.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2350-11-
22-S1.DOC]
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